A large-scale study identifies favorable treatment strategies for bipolar disorder patients who do not respond to lithium, offering clinical guidance for alternative pharmacotherapy.
The FDA has approved the first non-antipsychotic medication for treating agitation associated with Alzheimer's disease, marking a significant shift in pharmacologic management for this behavioral symptom.
The FDA has approved the first non-antipsychotic medication for treating agitation associated with Alzheimer's disease, marking a significant shift in pharmacological management for this behavioral symptom.
The FDA has approved the first non-antipsychotic medication for the treatment of agitation associated with Alzheimer's disease, offering a new prescribing option for this behavioral symptom.
Researchers identified a specific opioid receptor pathway and receptor cross-talk as the mechanism driving ketamine's rapid antidepressant effects.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Aug 22 – May 02)
- Prescribe Auvelity (dextromethorphan/bupropion) as a first-line non-antipsychotic alternative for agitation in Alzheimer's disease to mitigate the metabolic and extrapyramidal risks associated with typical antipsychotics.
- Leverage the newly approved indication for Auvelity to offer patients with Alzheimer's-related agitation a pharmacologic option with a distinct safety profile compared to traditional antipsychotics.
- Consider the identified opioid receptor cross-talk mechanism when managing patients with treatment-resistant depression, as it may inform the development or selection of novel rapid-acting antidepressants beyond standard ketamine protocols.
- Monitor for potential regulatory changes in your jurisdiction regarding ketamine therapy, as states like Texas are implementing tighter rules that may affect off-label prescribing practices and clinic operations.
- Utilize recent large-scale data on lithium non-responders in bipolar disorder to guide the selection of alternative pharmacotherapies earlier in the treatment course for patients who fail initial mood stabilizer trials.
- Evaluate the risks and benefits of polypharmacy during pregnancy by reviewing current data on the association between multiple non-opioid psychotropic co-exposures and short-term neonatal outcomes.
- Recognize that Auvelity is now indicated for agitation in Alzheimer's disease, expanding its utility beyond major depressive disorder and providing a targeted option for behavioral symptoms in dementia.
- Stay informed about the clinical trial data for inhaled DMT in Major Depressive Disorder, as emerging efficacy results may soon influence the landscape of rapid-acting antidepressant treatments.
- Approach the use of probiotics like PB-18 for mild to moderate depression with caution, recognizing that dietary supplements currently lack the robust regulatory oversight and standardized dosing of FDA-approved psychotropics.
- Apply the knowledge of ketamine's specific mechanism of action to better counsel patients on the neurobiological basis of its rapid antidepressant effects and the rationale for its use in treatment-resistant cases.
Diagnosis & Treatment 3
FDA approval of Auvelity (dextromethorphan-bupropion) as the first non-antipsychotic treatment for agitation associated with Alzheimer's disease, offering a new pharmacologic option with a different safety profile than typical antipsychotics.
A clinical trial is recruiting to evaluate the efficacy of the PB-18 probiotic as a dietary supplement for mild to moderate depression.
This study examines the association between the number of non-opioid psychotropic medications and co-exposures during pregnancy and short-term neonatal outcomes, providing data relevant to prescribing psychotropics in pregnancy.
Policy & Regulation 2
The FDA has approved Auvelity (dextromethorphan/bupropion) for the treatment of agitation associated with Alzheimer's disease, expanding its indication beyond major depressive disorder.
Texas is considering tighter regulatory rules for ketamine therapy as its use for mental health care expands, representing a significant policy shift affecting prescribing practices for this off-label psychotropic treatment.
Mechanism of Action 1
Research into the mechanism of ketamine's antidepressant effects aims to develop novel therapeutics for treatment-resistant depression.
Drug Development 2
Researchers at Weill Cornell Medicine have reverse-engineered ketamine's antidepressant effects to identify novel therapeutic strategies for treatment-resistant depression.
A clinical trial is recruiting participants to evaluate the efficacy of inhaled N,N-Dimethyltryptamine (DMT) for the treatment of Major Depressive Disorder.